Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Topley

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Kidney International. Supplement|February 12, 2004
The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluidLine Skoufos, Nicholas Topley, Laurinda Cooker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 25, 2016
Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid StudyMark R Lambie, James Chess, Angela M Summers, et al.
Frontiers in Physiology|March 6, 2019
Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis PatientsZanzhe Yu, Mark Lambie, James Chess, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2013
Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patientsChan-Yu Lin, Gareth W Roberts, Ann Kift-Morgan, et al.
Kidney International|June 18, 2004
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membraneJohn D Williams, Nicholas Topley, Kathrine J Craig, et al.
The Journal of Rheumatology|December 4, 2009
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosusHannes Cash, Manfred Relle, Julia Menke, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 9, 2014
Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patientsYeoungjee Cho, David W Johnson, David A Vesey, et al.
Journal of the American Society of Nephrology : JASN|August 29, 2009
Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysisGareth W Roberts, Duncan Baird, Kathleen Gallagher, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|October 9, 2014
Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane DysfunctionYeoungjee Cho, David W Johnson, David A Vesey, et al.
BMC Nephrology|January 14, 2014
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patientsYeoungjee Cho, David W Johnson, David A Vesey, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Kidney International. Supplement|February 12, 2004
The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluidLine Skoufos, Nicholas Topley, Laurinda Cooker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 25, 2016
Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid StudyMark R Lambie, James Chess, Angela M Summers, et al.
Frontiers in Physiology|March 6, 2019
Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis PatientsZanzhe Yu, Mark Lambie, James Chess, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2013
Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patientsChan-Yu Lin, Gareth W Roberts, Ann Kift-Morgan, et al.
Kidney International|June 18, 2004
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membraneJohn D Williams, Nicholas Topley, Kathrine J Craig, et al.
The Journal of Rheumatology|December 4, 2009
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosusHannes Cash, Manfred Relle, Julia Menke, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 9, 2014
Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patientsYeoungjee Cho, David W Johnson, David A Vesey, et al.
Journal of the American Society of Nephrology : JASN|August 29, 2009
Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysisGareth W Roberts, Duncan Baird, Kathleen Gallagher, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|October 9, 2014
Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane DysfunctionYeoungjee Cho, David W Johnson, David A Vesey, et al.
BMC Nephrology|January 14, 2014
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patientsYeoungjee Cho, David W Johnson, David A Vesey, et al.
Pageof 10